Breast Cancer Risk In Postmenopausal Osteoporotic Women Reduced By Lasofoxifene

Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute. Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue…

Lasofoxifene Helps Reduce Risk Of Bone Fractures, Breast Cancer, Heart Disease And Stroke

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That’s the finding of a new study in the latest issue of the New England Journal of Medicine…